Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

New England Journal of Medicine

Volumn 348, Issue 14, 2003, Pages 1309-1321

  Pitt, Bertram ^a,g   Remme, Willem ^b   Zannad, Faiez ^c   Neaton, James ^d   Martinez, Felipe ^e   Roniker, Barbara ^f   Bittman, Richard ^f   Hurley, Steve ^f   Kleiman, Jay ^f   Gatlin, Marjorie ^f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Sticares Cardiovascular Research Foundation   (Netherlands)

^c Ctr d'Invest Clinique de Nancy   (France)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Fundacion Rusculleda   (Argentina)

^f Pharmacia   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELECTIVITY; DYSPNEA; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; IMPOTENCE; MALE; MASTALGIA; MENTAL DISEASE; MORBIDITY; MORTALITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN APPENDAGE DISEASE; SKIN DISEASE; STROKE; SUDDEN DEATH; TREATMENT OUTCOME; URINARY TRACT DISEASE;

EID: 0037417252     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030207     Document Type: Article

References (27)

1. Pitt B, Zannad F, Kemme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
2. Rodríguez JA, Godoy I, Castro P, et al. Kamipril vs. espironolactona en el remodelamiento ventricular izquierdo post-infarto: randomizado y dobleciego. Rev Med Chile 1997;125:643-52.
3. Earr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiontensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
4. Bauersachs J, Heck M, Fraccarollo D, et al. Addition ofspironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39: 351-8.
5. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281:H647-H654.
6. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101: 594-7.
7. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces collagen turn-over, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35:30-4.
8. Pitt B, Keichek N, Metscher B, et al. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy. Am J Hypertens 2002;15:23A. abstract.
9. Kocha R, Martin-Berger C, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143:4828-36.
10. Schaefer A, Fraccarollo D, Hildemann S, et al. Inhibition ofplatelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition. Eur Heart J 2002; 23:Suppl:401. abstract.
11. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-5.
12. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-7.
13. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
14. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79-87.
15. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997; 126:296-306.
16. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clin Trials 1995;16:395-407.
17. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319:1492-5.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
20. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
21. Cleland JG, Chattopadhyay S, Khand A, Houghton T, Kaye GC. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7:229-42.
22. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810.
23. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.
24. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
25. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72.
26. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol Heart Circ Physiol 2002;283:H423-H433.
27. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000;86:645-53.